

TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

AN OPEN ACCESS JOURNAL FOCUSING ON CLOSING THE GAP BETWEEN "BENCH AND BEDSIDE"

Annual Report 2022

Editorial Office

Email: editor@tlcr.org





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

Outline of the Report

1. Basic Information
2. Honorary Editor-in-Chief
3. Editors-in-Chief
4. Editorial Board Members
5. Types of Articles Published in 2022
6. Citations of TLCR (results by year)
7. Website Visits
8. Most Cited Articles Published Between 2020 - 2021
9. Upcoming Special Series
10. Reviewers of the Month (2022)
11. Interviews with Outstanding Authors (2022)
12. Introduction to the Publisher AME




TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

1. Basic Information

- Open Access
- Peer Reviewed
- Launched in March 2012
- **Impact Factor: 4.726**
- Indexed by **Science Citation Index Expanded (SCIE)**, PubMed/PubMed Central, Scopus, Google Scholar, Medscape, Chemical Abstracts Service (CAS) Databases, MDlinx
- Published quarterly (Mar. 2012 - Jan. 2013), bimonthly (Feb. 2013 - Dec. 2020), and monthly (Jan. 2021 -)
- The first international journal focusing on closing the gap between “Bench and Bedside” in lung cancer and related thoracic diseases.





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

1. Basic Information

TLCR is the official publication of:

- General Hospital of Eastern Theater Command, Nanjing, China
- Society for Translational Medicine (STM), Hong Kong

TLCR is endorsed by:

- Spanish Lung Cancer Group (SLCG)
- Bonnie J. Addario Lung Cancer Foundation (ALCF)
- Brazilian Society of Thoracic Surgery (SBCT)



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

2. Honorary Editor-in-Chief



Fred R. Hirsch, MD, PhD

Center for Thoracic Oncology,
Tisch Cancer Institute at Mount
Sinai, USA



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

3. Editors-in-Chief



Yong Song, MD, PhD
General Hospital of Eastern
Theater Command, China




Caicun Zhou, MD, PhD
Shanghai Pulmonary
Hospital, China



Rafael Rosell, MD, PhD
Dexeus University
Institute, Spain



4. Editorial Board Members



86 in totality, including:

- 1** Honorary Editors-in-Chief
- 3** Editors-in-Chief
- 4** Associate Editors-in-Chief
- 1** Associate Editor
- 77** Editorial Board Members


Updated on Jan 4, 2023



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

5. Types of Articles Published in 2022



In 2022, TLCR published **230** articles, among which there are **160** Original Articles and **12** Review Articles.

TLCR embraces diverse article types to meet demands from international authors and readers. The major article types published in TLCR include Original Article, Review Article and Editorial.


Updated on Jan 4, 2023



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

6. Citations of TLCR (results by year)



The citations of TLCR has significantly increased to **4,203** in 2022.


Source: Web of Science Core Collection. Updated on Jan 4, 2023





7. Website Visits

Pageviews of TLCR Website in 2022



Country Users

1.	United States	141,528 (42.46%)
2.	India	28,204 (8.46%)
3.	China	26,919 (8.08%)
4.	United Kingdom	19,232 (5.77%)
5.	Canada	10,769 (3.23%)
6.	Australia	10,236 (3.07%)
7.	Japan	8,940 (2.68%)
8.	South Korea	6,796 (2.04%)
9.	Italy	5,962 (1.79%)
10.	Germany	5,321 (1.60%)

According to the data collected from Google Analytics, there are altogether **333,717** users and **748,496** pageviews in 2022. Readers who visited TLCR website form diverse countries, with the majority from United States, followed by India, China, United Kingdom and Canada.

Source: Google Analytics Jan 1, 2022 - Dec 31, 2022



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

8. Most Cited Articles Published Between 2020 - 2021

Corresponding Author(s)	Article Title
Emanuela Taioli	Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use
Caicun Zhou, Xuefei Li	Targeting ferroptosis for cancer therapy: exploring novel strategies from its mechanisms and role in cancers
David B. Chapel	Application of immunohistochemistry in diagnosis and management of malignant mesothelioma
Sylvie Lantuejoul	New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts
Shun Lu	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort
Steven G. Gray, Luciano Mutti	Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
Wenfeng Fang	PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
Giuseppe L. Banna	Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
Haining Yang	How asbestos and other fibers cause mesothelioma
Bing Gu, Bi Chen	Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer

Source: Web of Science Core Collection. Updated on Jan 4, 2023.



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

9. Upcoming Special Series

➤ “ALK-Positive NSCLC” edited by



Jessica J. Lin

Department of Medicine, Harvard
Medical School, Boston, USA



Justin F. Gainor

Department of Medicine, Harvard
Medical School, Boston, USA





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Reviewers of the Month (2022)

In 2022, many TLCR reviewers have made outstanding contributions to the peer review process. Hereby, we would like to highlight a few of them as follows in form of interview. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.




Yoshikane Yamauchi

Teikyo University School of
Medicine, Japan



Petros Christopoulos

Heidelberg University
Hospital, Germany



Yusuke Okuma

National Cancer Center
Hospital, Japan





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Reviewers of the Month (2022)



Giulio Metro

Santa Maria della Misericordia
Hospital, Italy



Samir Hanash

MD Anderson Cancer Center,
USA



John D. Minna

University of Texas Southwestern
Medical Center (1991-present), USA




TLCR
TRANSLATIONAL LUNG CANCER RESEARCH

10. Reviewers of the Month (2022)



María Rodríguez

Clinica Universidad de Navarra in Madrid, Spain



Jianjun Zhang

MD Anderson Cancer Center, USA



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

11. Interviews with Outstanding Authors (2022)

Over the years, many TLCR authors have made outstanding contributions to the journal. This column features interviews with our outstanding authors, who will share their unique thoughts and insights as scientific writers.



Elin S. Gray

Edith Cowan University,
Australia



Michael J. Sorich

Flinders University,
Australia



Per Hydbring

Karolinska Institutet,
Sweden





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

11. Interviews with Outstanding Authors (2022)



Hyun Koo Kim

Korea University Guro
Hospital, Republic of Korea



Paola Perego

Fondazione IRCCS Istituto
Nazionale dei Tumori,
Italy



Javier Pozas

Ramón y Cajal University
Hospital, Spain





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

11. Interviews with Outstanding Authors (2022)




Satoshi Watanabe

Niigata University Graduate
School of Medical and Dental
Sciences, Japan



Mariano Provencio

Hospital Universitario Puerta
de Hierro Majadahonda,
Spain



Tadaaki Yamada

Kyoto Prefectural University of
Medicine, Japan






TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

11. Interviews with Outstanding Authors (2022)



Jae Cheol Lee

University of Ulsan College of
Medicine, South Korea



Toshiyuki Sumi

Hakodate Goryoukaku Hospital, Japan



Andreas Dome

University of Antwerp, Belgium



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

11. Interviews with Outstanding Authors (2022)




Young-Chul Kim

Chonnam National University
Medical School and Hwasun
Hospital, South Korea



Pascal Hannequin

Annecy Nuclear Medicine
Center, France



Rafael Parra-Medina

Instituto Nacional de Cancerologia,
Columbia



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

12. Introduction to the Publisher AME

Meet our Publisher:

AME Publishing Company

- Established in 2009
- Registered in Hong Kong
- 10 offices around the world
- 60+ peer-reviewed journals
 - 13 indexed in SCIE
 - 7 indexed in ESCI
 - 20 indexed in PubMed/PMC/MEDLINE
- 200+ Medical Books
 - 80+ Medical Books in English
 - 120+ Medical Books in Chinese
- 150+ Electronic Editions





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

Thank You for All Your Support!